KYMR (NASDAQ) - Kymera Therapeutics Inc

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5015751044
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for KYMR (NASDAQ) - Kymera Therapeutics Inc


Market Cap in USD 1,100m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2020-08-21


Fundamental -7.25
Dividend -
Performance 5y -5.14
Rel. Performance vs Sector -6.78
Analysts 4.28
Fair Price Total Ret. 11.44
Fair Price DCF todo


Growth TTM -38.85%
CAGR 5y -24.56%
CAGR / Mean Drawdown 5y -0.49
Sharpe Ratio TTM -0.65
Alpha vs SP500 TTM -91.21
Beta vs SP500 5y weekly 2.66
CAPM 10.99%
Average Daily Range 2m 5.26%
Reversal Oscillator 2.70
Volatility GJR Garch 1y 60.58%
Price / SMA 50 -28.68%
Price / SMA 200 -48.4%
Current Volume 739.7k
Average Volume 20d 450.2k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%